Short Interest in Nuvilex Inc. (NASDAQ:PMCB) Declines By 24.4%

Nuvilex Inc. (NASDAQ:PMCB) saw a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 106,373 shares, a decrease of 24.4% from the February 12th total of 140,630 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily volume of 100,244 shares, the short-interest ratio is currently 1.1 days. Based on an average daily volume of 100,244 shares, the short-interest ratio is currently 1.1 days. Approximately 1.1% of the company’s stock are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Nuvilex to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Nuvilex Trading Down 0.7%

PMCB stock traded down $0.00 during midday trading on Friday, hitting $0.69. The company’s stock had a trading volume of 30,151 shares, compared to its average volume of 103,857. The firm’s 50-day moving average is $0.78 and its 200-day moving average is $0.87. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.73. The company has a market cap of $7.41 million, a PE ratio of -0.50 and a beta of 0.33.

Nuvilex (NASDAQ:PMCB) last posted its earnings results on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Insider Transactions at Nuvilex

In other Nuvilex news, CEO Joshua Silverman bought 40,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was acquired at an average price of $0.83 per share, with a total value of $33,200.00. Following the completion of the purchase, the chief executive officer owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. This trade represents a 10.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 110,000 shares of company stock valued at $89,000 in the last ninety days. 10.98% of the stock is currently owned by corporate insiders.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.